Bio-Rad Laboratories, Inc. (BIO-B) — SEC Filings
Bio-Rad Laboratories, Inc. (BIO-B) — 39 SEC filings. Latest: 10-Q (Oct 29, 2025). Includes 18 8-K, 9 SC 13G/A, 6 10-Q.
View Bio-Rad Laboratories, Inc. on SEC EDGAR
Overview
Bio-Rad Laboratories, Inc. (BIO-B) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Oct 29, 2025: BIO-RAD LABORATORIES, INC. reported a net loss of $341.9 million for the three months ended September 30, 2025, a significant decline from a net income of $653.2 million in the same period of 2024. This was primarily driven by a $495.3 million loss from the change in fair market value of equity secu
Sentiment Summary
Across 39 filings, the sentiment breakdown is: 1 bearish, 36 neutral, 2 mixed. The dominant filing sentiment for Bio-Rad Laboratories, Inc. is neutral.
Filing Type Overview
Bio-Rad Laboratories, Inc. (BIO-B) has filed 6 10-Q, 18 8-K, 2 DEF 14A, 2 10-K, 2 SC 13G, 9 SC 13G/A with the SEC between Jan 2024 to Oct 2025.
Filings by Year
Recent SEC Filings (39)
Risk Profile
Risk Assessment: Of BIO-B's 28 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $653.0M |
| Net Income | -$341.9M |
| EPS | -$12.68 |
| Debt-to-Equity | 0.44 |
| Cash Position | $395.8M |
| Operating Margin | N/A |
| Total Assets | $9,696.4M |
| Total Debt | $1,202.7M |
Key Executives
- Dr. Michael J. Gelb
- Ms. Susan J. Noack
- Mr. John W. Smith
- Mr. Michael J. Zody
- Sarah E. Young
- Michael Morton
- Ilan D. Danieli
- Ilan D. Daskal
Industry Context
Bio-Rad Laboratories operates in the life science research and clinical diagnostics markets. The industry is characterized by continuous innovation, demand for advanced analytical tools, and stringent regulatory oversight. Key trends include the growth of personalized medicine, advancements in genomics and proteomics, and the increasing use of automation in laboratories.
Top Tags
disclosure (5) · 8-K (4) · 10-Q (4) · financials (4) · regulation-fd (3) · quarterly-report (3) · executive-appointment (3) · compensation (3) · Bio-Rad Laboratories (3) · Biotechnology (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $341.9M | Significant swing from $653.2M net income in Q3 2024 |
| Loss from Equity Securities Valuation (Q3 2025) | $495.3M | Primary driver of net loss, contrasting with $792.9M gain in Q3 2024 |
| Net Sales (Q3 2025) | $653.0M | Slight increase from $649.7M in Q3 2024 |
| R&D Expense (Q3 2025) | $71.3M | Decrease from $91.0M in Q3 2024 |
| Net Income (9M 2025) | $39.9M | Improvement from $1,128.4M net loss in 9M 2024 |
| Loss from Equity Securities Valuation (9M 2025) | $129.1M | Significantly less than $1,680.3M loss in 9M 2024 |
| Total Assets (Sep 30, 2025) | $9,696.4M | Increased from $9,364.1M at Dec 31, 2024 |
| Goodwill, net (Sep 30, 2025) | $578.7M | Increased by $168.2M from $410.5M at Dec 31, 2024, indicating acquisitions |
| Cash and Cash Equivalents (Sep 30, 2025) | $395.8M | Decreased from $488.1M at Dec 31, 2024 |
| Weighted Average Common Shares - Basic (Q3 2025) | 26,923 | Decreased from 27,949 in Q3 2024 |
| Net Loss (Q2 2025) | -$10.1M | Significant swing from $10.0M net income in Q2 2024 |
| Net Loss (YTD 2025) | -$10.1M | Compared to $20.0M net income for YTD 2024 |
| Class A Shares Outstanding | 29.66M | As of July 28, 2025 |
| Class B Shares Outstanding | 2.0M | As of July 28, 2025 |
| Accumulated Other Comprehensive Income | $5.0M | Decreased from $10.0M at 2024-12-31 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Bio-Rad Laboratories, Inc. (BIO-B)?
Bio-Rad Laboratories, Inc. has 39 recent SEC filings from Jan 2024 to Oct 2025, including 18 8-K, 9 SC 13G/A, 6 10-Q. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of BIO-B filings?
Across 39 filings, the sentiment breakdown is: 1 bearish, 36 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Bio-Rad Laboratories, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Bio-Rad Laboratories, Inc. (BIO-B) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Bio-Rad Laboratories, Inc.?
Key financial highlights from Bio-Rad Laboratories, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for BIO-B?
The investment thesis for BIO-B includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Bio-Rad Laboratories, Inc.?
Key executives identified across Bio-Rad Laboratories, Inc.'s filings include Dr. Michael J. Gelb, Ms. Susan J. Noack, Mr. John W. Smith, Mr. Michael J. Zody, Sarah E. Young and 3 others.
What are the main risk factors for Bio-Rad Laboratories, Inc. stock?
Of BIO-B's 28 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 19 low-risk.
What are recent predictions and forward guidance from Bio-Rad Laboratories, Inc.?
Forward guidance and predictions for Bio-Rad Laboratories, Inc. are extracted from SEC filings as they are enriched.